Lankisch Tim O, Vogel Arndt, Eilermann Stefan, Fiebeler Anette, Krone Britta, Barut Ayse, Manns Michael P, Strassburg Christian P
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany.
Mol Pharmacol. 2005 May;67(5):1732-9. doi: 10.1124/mol.104.007146. Epub 2005 Feb 16.
UDP glucuronosyltransferases (UGT) detoxify bilirubin and therapeutic drugs, a process influenced by single nucleotide polymorphisms (SNPs) in their structural genes and promoter elements. UGT1A128 is a functional UGT promoter polymorphism associated with Gilbert's disease and severe irinotecan toxicity, which also occurs in the absence of UGT1A128. The aim of this study was to identify and characterize UGT promoter variants relevant for irinotecan detoxification. Recombinant UGT1A proteins were analyzed for irinotecan metabolite glucuronidation by UGT activity assays. In 427 healthy blood donors and 71 homozygous UGT1A128 carriers, the 5'-untranslated region of the UGT1A7 gene locus was studied. An SNP was detected by allelic discrimination and characterized by reporter gene experiments. A novel -57 T--> G SNP with a gene frequency of 0.39 in healthy blood donors was identified in the putative TATA box of the UGT1A7 gene, reducing promoter activity to 30%. It is in linkage dysequilibrium with a variant of the UGT1A7 first exon that is present in the reduced-activity UGT1A73 and UGT1A74 alleles. Homozygous UGT1A128 carriers simultaneously carried this variant in 97%. We identified a novel reduced-function TATA box SNP of the UGT1A7 gene that catalyzes irinotecan metabolite detoxification. Its association with variants of the UGT1A1 promoter and UGT1A7 gene may influence irinotecan metabolism. Our finding emphasizes the importance of combinations of structural and regulatory gene polymorphisms that may be useful as markers of drug toxicity.
尿苷二磷酸葡萄糖醛酸基转移酶(UGT)可使胆红素和治疗药物解毒,这一过程受其结构基因和启动子元件中的单核苷酸多态性(SNP)影响。UGT1A128是一种功能性UGT启动子多态性,与吉尔伯特病和严重的伊立替康毒性相关,在不存在UGT1A128的情况下也会出现这种毒性。本研究的目的是鉴定和表征与伊立替康解毒相关的UGT启动子变体。通过UGT活性测定分析重组UGT1A蛋白对伊立替康代谢物的葡萄糖醛酸化作用。在427名健康献血者和71名纯合UGT1A128携带者中,研究了UGT1A7基因座的5'非翻译区。通过等位基因鉴别检测到一个SNP,并通过报告基因实验对其进行表征。在UGT1A7基因的假定TATA框中鉴定出一种新的-57 T→G SNP,在健康献血者中的基因频率为0.39,可将启动子活性降低至30%。它与UGT1A7第一外显子的一个变体处于连锁不平衡状态,该变体存在于活性降低的UGT1A73和UGT1A74等位基因中。97%的纯合UGT1A128携带者同时携带此变体。我们鉴定出一种新的功能降低的UGT1A7基因TATA框SNP,它催化伊立替康代谢物解毒。它与UGT1A1启动子和UGT1A7基因变体的关联可能会影响伊立替康的代谢。我们的发现强调了结构和调控基因多态性组合的重要性,这些组合可能作为药物毒性的标志物。